For the first time, we describe the expression of NK1R and its truncated splice variant in rhabdoid tumors, and that it can be targeted with NK1R antagonist aprepitant, serving as a novel target for the treatment of RT. The gene discussed is TACR1; the disease is rhabdoid tumor.